-
The Great Care Conundrum: What “Good” Care Looks Like in Huntington’s Disease
Latest News
-
Huntington's Disease Therapeutics Conference 2017 – Day 1
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta – day 1
-
Enemy at the gates – huntingtin disrupts nuclear transport
Two recent studies show how a cellular border control system goes wrong in HD, opening new avenues for HD research.
-
FDA approves a new drug for symptoms of Huntington's disease
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease
-
Sheep leading the flock: metabolism and biomarkers in HD
Sheep can help us to identify HD biomarkers and recognize metabolic changes that occur before symptoms develop.
-
Weeding out the truth: can cannabis improve Huntington’s?
What can individual experiences with cannabis tell us about Huntington's disease?
-
Huntingtin grabs a hammer: DNA repair in HD
Huntingtin helps fix damaged DNA, a recent study suggests, under the direction of a gene repair protein called ATM.
-
The benefits of migration, highlighted in Huntington's disease
Is HD a developmental disease? HD stops neurons migrating in developing brain, but maybe we can get them going again
-
Treasure your exceptions – using outliers to understand Huntington's disease onset and progression
A new study provides the framework for finding factors that affect the onset and progression of HD
-
A powerful message: does a toxic RNA message molecule cause harm in Huntington's disease?
What if some problems in HD were due to something other than a harmful protein?
-
Pfizer Amaryllis trial ends in disappointment: no improvement in Huntington's disease symptoms
Pfizer announces the 'Amaryllis' trial of a PDE-10 inhibitor drug failed to improve symptoms of HD
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
